SCHEMBL6156954

SCHEMBL6156954

NCc1cccc(NN(C(=O)Nc2ccc(N3CCOCC3)c(Cl)c2)c2ccccc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.51
RAB9A P51151 9/20 0.51
NPC1 O15118 8/20 0.51
TP53 P04637 2/20 0.51
MAPT P10636 9/20 0.50
LMNA P02545 7/20 0.50
MEN1 O00255 6/20 0.50
KMT2A Q03164 6/20 0.50
MAPK1 P28482 2/20 0.50
ALDH1A1 P00352 9/20 0.48
HPGD P15428 4/20 0.48
HTT P42858 5/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
ALOX12 P18054 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TSHR P16473 2/20 0.46
L3MBTL1 Q9Y468 3/20 0.45
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6157583 0.91 MAPT (0.47) SMN1; SMN2RAB9ANPC1TP53MAPT
SCHEMBL6156079 0.88 F10 (0.44) SMN1; SMN2RAB9ANPC1TP53MAPT
SCHEMBL6156558 0.81 RAB9A (0.52) SMN1; SMN2RAB9ANPC1TP53MAPT
SCHEMBL6158826 0.81 ALDH1A1 (0.43) SMN1; SMN2TP53MAPTMEN1KMT2A
SCHEMBL6156474 0.78 F10 (0.47) CYP2C9
SCHEMBL6156412 0.76 KDM1A (0.41) SMN1; SMN2MAPTTSHR
SCHEMBL6156664 0.75 TP53 (0.40) SMN1; SMN2RAB9ANPC1TP53MAPT
SCHEMBL6376838 0.74 RORC (0.39) SMN1; SMN2RAB9ANPC1MAPTMEN1
SCHEMBL6157569 0.74 TP53 (0.38) SMN1; SMN2RAB9ANPC1TP53LMNA
SCHEMBL6156058 0.74 F10 (0.44) SMN1; SMN2RAB9ANPC1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US claimed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP claimed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO claimed
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US disclosed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP disclosed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases SERPINC1, F11, F12 SMN1; SMN2 3250/4885RAB9A 1150/4885NPC1 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.